[Effects of Oridonin combined with Capecitabine on the proliferaction of MDA-MB-231 human breast cancer cells].

Objective: To investigate the effects of oridonin combined with capecitabine on the proliferaction of MDA-MB-231 human breast cancer cells. Methods: Effect of different concentrations(10, 20 and 40 μmol/L)of oridonin, capecitabine and their combination on the proliferation of MDA-MB-231 cells after incubation for 24 or 48 h was studied. Then, the effect of 5 μmol/L of oridonin, capecitabine and their combination on cell colony formation was detected. Finally, influence of 20 μmol/L of oridonin, capecitabine and their combination on morphological alteration of nucleus, cell cycle and apoptosis was explored. Results: The inhibition rate on MDA-MB-231 cells after incubation with 20 μmol/L oridonin or capecitabine for 48 h was 49.5% and 58.6%, respectively, while the inhibition rate against proliferation of MDA-MB-231 cells reached 94.6% with combination of 20 μmol/L oridonin and capecitabine. Cells incubated with combination of oridonin and capecitabine formed fewer and smaller colonies (P<0.01). Meanwhile, cells in the combination group arrested at S and G2/M phases at the same time, and combination of two drugs caused more apoptotic cells (P<0.01). Conclusion: Oridonin combined with capecitabine can synergistically inhibit the proliferation of MDA-MB-231 human breast cancer cells.目的： 观察冬凌草甲素联合卡培他滨对乳腺癌MDA-MB-231细胞增殖的影响。 方法： 观察不同浓度(10、20及40 μmol/L)的冬凌草甲素和卡培他滨及其两者联合用药与MDA-MB-231细胞孵育24和48 h的细胞存活率。考察5 μmol/L的冬凌草甲素和卡培他滨及其两者联合使用对MDA-MB-231细胞集落形成的影响。考察20 μmol/L的冬凌草甲素和卡培他滨及其两者联合使用对MDA-MB-231细胞核形态，细胞周期及凋亡的影响。 结果： 冬凌草甲素和卡培他滨在20 μmol/L孵育48 h对MDA-MB-231细胞的抑制率分别为49.5%和58.6%，而将两者联合使用时，对肿瘤的抑制率达到94.6%。联合给药后肿瘤集落形成的大小和个数较单独给药时明显减少(P<0.01)。同时给予冬凌草甲素和卡培他滨，可将细胞同时阻滞于S期和G2/M期，凋亡细胞的比例也有显著升高(P<0.01)。 结论： 将冬凌草甲素与卡培他滨联合给药之后，两者可以协同起效，共同发挥抗肿瘤效果，对乳腺癌MDA-MB-231细胞的增殖起到显著的抑制作用。.